Dermatologist Preferences for First-Line Therapy of Moderate-to-Severe Psoriasis in Healthy Adults

被引:0
作者
Wan, Joy [1 ]
Abuabara, Katrina [1 ]
Troxel, Andrea B. [1 ]
Shin, Daniel B. [1 ]
Van Voorhees, Abby S. [1 ]
Bebo, Bruce F., Jr. [2 ]
Krueger, Gerald G. [3 ]
Duffin, Kristina Callis [3 ]
Gelfand, Joel M. [1 ]
机构
[1] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
[2] Natl Psoriasis Fdn, Portland, OR USA
[3] Univ Utah, Sch Med, Salt Lake City, UT USA
关键词
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
261
引用
收藏
页码:S113 / S113
页数:1
相关论文
共 50 条
[21]   Deucravacitinib in moderate-to-severe psoriasis [J].
Vu, Alan ;
Maloney, Victoria ;
Gordon, Kenneth B. .
IMMUNOTHERAPY, 2022, 14 (16) :1279-1290
[22]   COST-EFFECTIVENESS OF FIRST-LINE BIOLOGICS FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS [J].
Beilman, Candace L. ;
Fedorak, Richard N. ;
Halloran, Brendan P. .
GASTROENTEROLOGY, 2019, 156 (06) :S260-S261
[23]   Portuguese consensus on first line treatment of moderate-to-severe psoriasis with a non-TNF inhibitor therapy - a delphi methodology [J].
Torres, Tiago ;
Magina, Sofia ;
Lopes, Maria Joao Paiva .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2025, 36 (01)
[24]   Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium [J].
Carmona-Rocha, Elena ;
Puig, Lluis .
IMMUNOTHERAPY, 2023, 15 (15) :1209-1225
[25]   Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection [J].
Tian, Q. ;
Si, J. ;
Jiang, F. ;
Xu, R. ;
Wei, B. ;
Huang, B. ;
Li, Q. ;
Jiang, Z. ;
Zhao, T. .
HIV MEDICINE, 2021, 22 (04) :307-313
[26]   First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid [J].
Cho, Y. T. ;
Chu, C. Y. ;
Wang, L. F. .
BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (01) :302-304
[27]   Use of systemic and biological therapy in patients with moderate-to-severe psoriasis [J].
Liljendahl, Mie S. ;
Loft, Nikolai ;
Nguyen, Tri-Long ;
Skov, Lone ;
Egeberg, Alexander .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 49 (01) :35-41
[28]   Ixekizumab in the treatment of moderate-to-severe plaque psoriasis: Patient adherence, satisfaction, and preferences [J].
Azhar, Aaminah ;
Zaayman, Marcus ;
Silfvast-Kaiser, Annika ;
Kivelevitch, Dario ;
Menter, Alan ;
Paek, So Yeon .
DERMATOLOGIC THERAPY, 2021, 34 (01)
[29]   IMMUNOMODULATOR CO-THERAPY IMPROVES MEDICATION PERSISTENCE OF FIRST-LINE ANTI-TUMOR NECROSIS FACTOR AGENTS AND FIRST-LINE VEDOLIZUMAB, BUT NOT SECOND-LINE THERAPY, IN MODERATE-TO-SEVERE ULCERATIVE COLITIS [J].
Pudipeddi, Aviv ;
Ko, Yanna ;
Paramsothy, Sudarshan ;
Leong, Rupert W. .
GASTROENTEROLOGY, 2021, 160 (06) :S343-S344
[30]   French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults [J].
Amatore, F. ;
Villani, A. -P. ;
Tauber, M. ;
Viguier, M. ;
Guillot, B. ;
Aubin, Francois ;
Bachelez, Herve ;
Beneton, Nathalie ;
Beylot-Barry, Marie ;
Jullien, Denis ;
Mahe, Emmanuel ;
Paul, Carle ;
Richard, Marie-Aleth .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (03) :464-483